(NASDAQ: PYXS) Pyxis Oncology's forecast annual revenue growth rate of 52.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.25%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.49%.
Pyxis Oncology's revenue in 2025 is $2,820,000.On average, 3 Wall Street analysts forecast PYXS's revenue for 2025 to be $178,178,102, with the lowest PYXS revenue forecast at $173,650,778, and the highest PYXS revenue forecast at $186,054,405. On average, 1 Wall Street analysts forecast PYXS's revenue for 2027 to be $744,217,620, with the lowest PYXS revenue forecast at $744,217,620, and the highest PYXS revenue forecast at $744,217,620.
In 2028, PYXS is forecast to generate $4,527,323,855 in revenue, with the lowest revenue forecast at $4,527,323,855 and the highest revenue forecast at $4,527,323,855.